Snofi Phanma

Team Project
Table of Contents
Preface and Acknowledgment.........................................................................................................2
Preface.........................................................................................................................................2
Acknowledgement.......................................................................................................................2
Introduction.....................................................................................................................................3
Profile of Organization.....................................................................................................................4
History..........................................................................................................................................4
Therapeutic Areas and Products.................................................................................................5
Vision Statement.........................................................................................................................5
Mission Statement.......................................................................................................................5
Objective & Goals........................................................................................................................6
Objectives................................................................................................................................6
Goals........................................................................................................................................6
Core Values..............................................................................................................................6
Problem Area...............................................................................................................................6
Benchmark...................................................................................................................................6
Data Collection.................................................................................................................................7
Objectivity of Study.....................................................................................................................7
Data Collection.............................................................................................................................7
Execution of the Project/Analysis against benchmark................................................................7
Findings, Conclusions, Suggestions/Recommendations & Limitations...........................................8
Findings........................................................................................................................................8
Conclusion....................................................................................................................................8
Recommendations & Suggestions...............................................................................................9
Limitation.....................................................................................................................................9
Preface and Acknowledgment

Preface
This is the final report for our project in our HRTP and HRM course, which is required by our
course instructor, Dr. Khizar Hayat Khan. The purpose of this report is to put the concepts
learned in this course into practice. In our project, we worked with the company "SANOFI
Pakistan".

Acknowledgement
I greet you in the name of Allah, The Most Gracious, The Most Merciful. We would like to
express our gratitude to the Almighty Allah for providing us with the capability and stamina to
complete our project for future study. We were given direction so that we could approach this
report as a challenge, and in the end, He blessed us.
A work is never the creation of a single person. This project would not have been completed
without the support and guidance of our esteemed Teacher, a lecturer at Iqra University, who
provided invaluable guidance, comments, ideas, and suggestions throughout the course.
A special thank you to our team members, who gave their all to make this project the best it
could be. During this course, we all learned new things and gained useful experience.
Introduction
Sanofi S.A. is a French pharmaceutical and healthcare multinational with its headquarters in
Paris. The company was initially founded in 1973, then in 1999 it combined with Synthélabo to
form Sanofi-Synthélabo. Sanofi-Synthélabo and Aventis, both the result of multiple prior
mergers, united to form Sanofi-Aventis in 2004. In May 2011, it returned to using the name
Sanofi.
Sanofi develops over-the-counter medicines in addition to doing research, developing,
producing, and marketing pharmaceutical products, mostly for the prescription market. Seven
key therapeutic areas are covered by the company: cardiovascular, diabetes, internal medicine,
oncology, thrombosis, and vaccines.
Position in both mature and developing markets that is quite comprehensive and well-rounded.
More than 110,000 employees working in 100 different countries, with a net worth of €33
billion in 2013 and a net revenue of €37.76 billion in 2021.
Profile of Organization
A leader in worldwide and varied healthcare, SANOFI finds, creates, and disseminates
therapeutic solutions that are patient-centered. Sanofi offers 11 growth pillars, including
diabetic solutions, human vaccines, innovative pharmaceuticals, consumer healthcare,
developing markets, cardiology, vaccination, and nephrology, that contribute to its capabilities
in the healthcare sector. Sanofi's presence in the field of rare diseases has been significantly
increased with the acquisition of Genzyme.

History
Millions of lives have been saved and countless others' quality of life has been improved since
the company that is now known as Sanofi Pakistan first came in Pakistan more than 50 years
ago thanks to its effective, high-quality products.
The company was founded as Hoechst Pakistan Limited on December 8, 1967. Pharmaceutical
and specialized chemical manufacture started in 1972. In 1977, the company went public and
was listed on the Pakistan Stock Exchange. Agrochemical formulation started in 1985.
The following year, the Specialty Chemicals business was sold to Clariant Pakistan Limited, while
the Agriculture business was separated out in 1996 to become AgrEvo Pakistan (Private)
Limited, a new legal entity. Hoechst Pakistan Limited changed its name to Hoechst Marion
Roussel (Pakistan) Limited in June 1996, and starting that month, its sole focus remained on
activities connected to the pharmaceutical industry.
In order to create Aventis S.A., Hoechst AG and Rhone Poulenc S.A. combined their respective
life sciences operations globally in December 1999. The company in Pakistan changed its name
to Aventis Pharma (Pakistan) Limited in November 2000.
In accordance with the global merger, Aventis Pharma (Pakistan) Limited and Rhone Poulenc
Rorer Pakistan (Private) Limited merged locally. As a result, the company started functioning as
Aventis Limited in April 2003.
Sanofi Synthelabo acquired Aventis S.A. in 2004 to form Sanofi-Aventis S.A. As a result, the
corporation's name was changed to Sanofi-Aventis Pakistan Ltd in September 2005.
In 2011, Sanofi-Aventis changed their name to Sanofi. Sanofi-Aventis Pakistan Limited is still the
organization's legal name, nonetheless.
Packages Limited announced publicly on December 20, 2021, that its Board of Directors had
given the company's membership in an investor consortium approval in principle so that the
consortium could investigate the possibility of buying the entire 52.87% of the company's
shares held by parent company Sanofi Foreign Participations B.V. IGI Investments and the
affiliates of the Arshad Ali Gohar Group make up the Consortium, which is led by Packages
Limited. In exchange, the Consortium was granted permission by the Parent Company to fully
probe the Company. However, until the completion of this yearly report, there had been no
significant advancement.
There are currently no assurances that the deal will proceed at all or that the discussions
between Sanofi and the Consortium will end in a binding agreement.
In February 2022, Sanofi unveiled a fresh global brand identity and logo. The old slogan,
"Empowering Life," has been replaced with "We chase the wonders of science to better
people's lives."

Therapeutic Areas and Products

Company covers major therapeutic areas

 Diabetes: In Diabetes, Sanofi offers Amaryl, Amaryl MSR, Daonil and Neodipar in oral
anti Diabetics solution. And in Insulin’s Sanofi has products of Lantus, Toujeo, Apidra
and Soliqua
 Oncology: In Oncology, Sanofi offers 4 products namely Jevtana, Taxotere, Eloxatin and
Fludara.
 Pain management: In Pain management, Sanofi has 4 products Nospa, Muscoril,
Profenid and Stemetil.
 Allergy management: In Allergy management, Sanofi has 6 medicines Telefast, Telefast
D, Avil, Tixylix, Nasacort AQ and Phenergan.
 Antibiotics: In Antibiotics, Sanofi has Claforan, Orelox, Targocid Tarivid, Tavanic and
Aventriax.
 Diarrhea: In Diarrhea, Sanofi has Flagyl, Flagyl Plus and Enterogermina
 Cardiology: In Cardiology, Sanofi has Plavix, Approvel, Co-approvel, Tritace, Co-tritace,
Winstor, Lasix and Lasoride, and Clexane.
 Emergency Care: In Emergency Care, Sanofi has 1 product namely Heamaccel
 Vaccine: In Sanofi Pasteur they have products IPOL vaccine, Menquadfi, Pentacel,
Quadracel, Tenivac, Tubersol, Typhim VI, Imovax Rabies, ActHIB, Adacel, Daptacel, and
Imogam
 Consumer Healthcare: In Consumer Healthcare, Sanofi has a product namely Selsun
blue.
 Nephrology: In Nephrology, Sanofi has a product namely Renvela

Vision Statement
Sanofi’s vision is “We chase the miracles of science to improve people’s lives”

Mission Statement
Sanofi’s mission is to support people as a health journey partner. Wherever people live and
whenever we can make a difference, we seek to protect, enable and support those who face
health challenges so they can live life to its full potential.
Objective & Goals
Objectives
According to the association's mission statement, Sanofi is committed to improving how they
run their business operations while assisting in addressing global challenges and producing
sustainable shared value.
Goals
Their goal is to improve people's lives, so we look for scientific wonders.
Core Values
Our values define our activities, ethics, and sense of ethics, ultimately becoming the DNA of our
firm.

 Courage: Take chances, innovate boldly, and learn from your errors.
 Teamwork: We are working hard to improve people's lives and be successful as One
Sanofi.
 Respect: Recognizing and valuing the diversity, range of opinions, and needs of our
customers, clients, and communities.
 Integrity: To uphold the greatest moral and professional standards, conduct yourself
with honesty and openness.

Problem Area
Located in Paris, France, Sanofi S.A. is a multinational French pharmaceutical and healthcare
public limited business. In Pakistan, Sanofi Aventis essentially failed as a pharmaceutical and
healthcare company, and all of its shares were sold off in December 2021. The reasons why
Sanofi failed in Pakistan are listed here.

 Sanofi worldwide policies are neither appropriate or helpful for the Pakistani market.
 No sustained rollout of a gold standard product.
 As a result of governmental initiatives, rising dollar rates, and declining profit margin.
 A dispute with the French authorities on the protection of the holiness of the Messenger
and the defense of the Din Blame game's inviolability from vulgar marketing in France.
In response, consumers inflicted a boycott on French goods, reduced their use, and the
corporation experienced losses in Pakistan.

Benchmark
 Enhance economic performance and achieve top ranking within five years.
 Introduce a product that meets the needs of the consumer and adheres to the highest
standards of quality.
 Reliable MNC rivals like Novo Nordisk and Eli Lilly.
 Establish company policies that are most suited to the Pakistani market.
 Achieving Goals Through 2022 and Beyond.
Data Collection
Objectivity of Study
 What caused Sanofi Aventis' business to decline?
 Why does Sanofi Aventis' economic metric fall short of the benchmark goal?
 Why did Sanofi Aventis close its operation in Pakistan?
 Why was Sanofi Aventis unable to achieve prior set goals?
 Why are its product costs higher than those of its competitors?
 Why is Sanofi Aventis unable to effectively market its products through social media,
newspapers, billboards, websites, and other channels by using appealing advertising
strategies?
 Why has Sanofi Aventis been unable to establish a dominant position and increase its
market share?
 Why is Sanofi Aventis unable to produce enough of its product in Pakistan to meet
demand?

Data Collection
 Data was gathered from direct interviews and focus groups, and feedback was gathered.
 Through a physical questionnaire survey, input was received
 By monitoring how customers engage with the business and its products and being able
to see it in action.

Execution of the Project/Analysis against benchmark

Procedures for showcasing are dynamic. New requests, needs, and inclinations come at each
age. Advancements in data and communication also started to emerge. Such aspects disrupt
the marketing, advertising, and commercial strategies employed by many business parts.

 Sanofi Pakistan continues to be one of the top 10 multinational corporations, closely

competing with Novo Nordisk and Eli Lilly. Sanofi Pakistan uses dynamic, imaginative,
and original advertising strategies that focus on customer specificities in order to
compete globally for the powerful buyer needs.
 Introduce a product that meets the needs of the consumer and adheres to the highest
standards of quality. As with its prior gold standard goods Amaryl, Lantus, and flagyl,
etc., Sanofi has to introduce more gold standard drugs to maintain its position in the
market and boost profits.
 Sanofi International has many restrictions compared to regional businesses because
their rules are universally applied. But in order to accomplish its objectives, Sanofi
Pakistan changes its rules regarding both its employees and customers.
 Sanofi is doing well financially because localization eliminates the impact of currency
exchange. (France)
 The implementation of policies following localization demonstrates the company's
success and indicates that future goals will be met as well.
We acknowledge that this investigation will help us gain knowledge of the Sanofi Pakistan
Company and its intended course of action.

Findings, Conclusions, Suggestions/Recommendations &

Limitations
Findings
 Because of a decline in revenue Additionally, the devaluation of the currency increased
production costs by about 70% of income. The dollar exchange rate was about 150 in
May 2021, and as of December 2022, it is presently 222.
 Due to uncertainties, rising fuel, electricity, labor, and raw material costs, as well as
DRAP price restrictions and firm profit declines, Sanofi Pakistan Pharma Company was
unable to reach benchmark targets. As a result, supply is decreasing.
 Sanofi Pakistan Company ceased operations in Pakistan in 2021 as a result of a
significant increase in import, packaging, and raw material taxes as well as operating at
a loss.
 Because the budget is insufficient and local businesses are swiftly conquering the
market with low costs and high profit margins.
 The cost of production is higher than that of local businesses due to research, the
upholding of international quality standards, and the direct importation of goods from
first-world nations.
 Sanofi global policies prohibit effective product advertising on social media platforms
including Twitter, Instagram, YouTube, newspapers, billboards, websites, and other
sources since it is expensive.
 Sanofi cannot tarnish its reputation in order to gain additional revenue for a client's
personal projects because of its high and strong ethical standards in the pharmaceutical
industry. However, other businesses are enabling and satisfying all of their customers'
requirements, wants, and expectations while making their customers happy, which
makes it difficult for them to achieve positive delta growth by year's end in 2021.
 A supply chain issue prevented Sanofi Aventis from meeting demand and supply for
their product in Pakistan. After COVID-19, this issue has experienced an unparalleled
global upheaval. In actuality, this is one of the biggest difficulties the pharmaceutical
business has had in the last ten years.

Conclusion
We all understand that some multinational corporations (MNCs) like Novo Nordisk and Eli Lilly
as well as all domestic businesses understand their customers' basic needs and respond
accordingly. As a result, they benefit and gain a significant market share, but Sanofi fails in
Pakistan because it is restricted by the same policies and procedures and refuses to adapt. As a
result, it meets its demise. It also fails as a result of inadequate attention paid to the advertising
campaign. Modern items considerably reduce its business. Uncertainty in the market and the
rising dollar rate are further factors that prevent changes in product prices. Sanofi Global
struggles to perform better since it did not alter its policies to meet the needs of the Pakistani
market.
However, Sanofi Pakistan is inclining once again after 2021, and delta positive increase has been
shown as a result of the change implemented after National setup and reclaimed its popularity.

Recommendations & Suggestions

 Instead of using a passionate approach, the Sanofi Pakistan group of executives uses an
objective methodology for the advancement of their product, which entails emphasizing
the product credits in the commercials. They should therefore use a passionate
methodology in their promos to entice more customers if they want to be more
successful in their advertising campaign.
 Reduce product costs.
 Simplify operation and paper workflows.

Limitation
 The complete price freeze on Sanofi's pharmaceutical products is the company's largest
obstacle.
 The other problem is that it typically takes years for new compounds to be approved,
depriving patients of the advantages of the most recent treatment.
 Unethical marketing.
 Accessibility to affordable healthcare.
 Disruption of the supply chain.